SUMMARY. The biomechanical and biochemical properties of collagen are changed by non-enzymatic glycation culminating in increased cross-linking. We have previously shown that dibasic amino acids such as L-arginine inhibit in vitro the non-enzymatic glycation of soluble proteins and insoluble connective tissue macromolecules. In the present in vitro study we obtained evidence that the nucleophilic hydrazine derivative aminoguanidine and the non-steroidal antirheumatic drug ibuprofen inhibit the formation of fluorescent advanced glycation end products (AGEs) to a comparable extent, while arginine is ineffective as a consequence of its tendency to form AGEs itself. Periodic replacement of glycated arginine in the rat tail tendon system, however, engendered an inhibition of fluorescence similar to that obtained by the other inhibitors. Long-term glycation of rat tail tendons caused a significant increase in Young's modulus, which could also be inhibited by periodically renewed arginine. In contrast to ibuprofen, aminoguanidine and arginine-lysine inhibited the marked increase in maximum contraction force of long-term glycated rat tail tendons. As opposed to other inhibitors, aminoguanidine also reduced the thermal contraction force of native tendons, shifted the maximum contraction temperature to markedly lower values and solubilized a significant part of the rat tail tendon collagen. These findings indicate that the in vitro alterations of rat tail tendon collagen induced by nonenzymatic glycation can be prevented by arginine, arginine-lysine and aminoguanidine. However, collagen structure is seriously affected by aminoguanidine.
SUMMARY. The biomechanical and biochemical properties of collagen are changed by non-enzymatic glycation culminating in increased cross-linking. We have previously shown that dibasic amino acids such as L-arginine inhibit in vitro the non-enzymatic glycation of soluble proteins and insoluble connective tissue macromolecules. In the present in vitro study we obtained evidence that the nucleophilic hydrazine derivative aminoguanidine and the non-steroidal antirheumatic drug ibuprofen inhibit the formation of fluorescent advanced glycation end products (AGEs) to a comparable extent, while arginine is ineffective as a consequence of its tendency to form AGEs itself. Periodic replacement of glycated arginine in the rat tail tendon system, however, engendered an inhibition of fluorescence similar to that obtained by the other inhibitors. Long-term glycation of rat tail tendons caused a significant increase in Young's modulus, which could also be inhibited by periodically renewed arginine. In contrast to ibuprofen, aminoguanidine and arginine-lysine inhibited the marked increase in maximum contraction force of long-term glycated rat tail tendons. As opposed to other inhibitors, aminoguanidine also reduced the thermal contraction force of native tendons, shifted the maximum contraction temperature to markedly lower values and solubilized a significant part of the rat tail tendon collagen. These findings indicate that the in vitro alterations of rat tail tendon collagen induced by nonenzymatic glycation can be prevented by arginine, arginine-lysine and aminoguanidine. However, collagen structure is seriously affected by aminoguanidine.
Additional key phrases: aminoguanidine; arginine-lysine; ibuprofen; L-arginine; isometric thermal contraction
It is now established that non-enzymatic addition reactions occur in vivo as well as in vitro between glucose and free aminogroups on proteins, especially at elevated glucose levels as observed in patients with diabetes.' The initial reaction is the formation of Schiff's bases, which are transformed in a sequence of multiple rearrangements into irreversible adducts-termed advanced glycation end products (AGE). On longer-lived macromolecules of the extracellular matrix AGE accumulate over time as a function of age and hyperglycaernia.! AGEs have been implicated in many of the late complications of Correspondence: Dr Ernst Johannes Menzel, Institute of Immunology, Borschkegasse Sa, A-1090 Vienna, Austria. diabetes and normal ageing." Different ways of pharmacological intervention were devised to inhibit this process, of which the nucleophilic hydrazine compound aminoguanidine, dibasic amino acids and the putative anti-cataract drug ibuprofen-" are the most promising.
Aminoguanidine has been shown to inhibit AGE-formation in vitro and to prevent several complications of diabetes in a number of experimental animal models. 4 ,7,8 Following the original suggestion of Sensi et al. 9 to use lysine as an inhibitor of non-enzymatic glycation, we tested the inhibitory effects of lysine and arginine in a rat tail tendon model and found that arginine is more efficient in inhibiting longterm biochemical and biomechanical changes due to non-enzymatic glycation.P In the present study we compared the in vitro effects of arginine and arginine-lysine on non-enzymatic glycation with those of the chemically related agent aminoguanidine and those of ibuprofen using a soluble protein as well as rat tail tendons as targets for long-term glycation.
MATERIALS AND METHODS

Rat tail tendons
We used tail tendons of 35 and l80-day-old Sprague-Dawley rats. The rats were killed with an overdose of pentobarbital. The tendons were dissected free and single tendon fibres were pulled from the proximal end. The tendon fibres were washed extensively in phosphate buffered saline [(PBS) 20mmol/L phosphate, 130mmol/L NaCl, pH 7,2]. The cross-sectional areas of the tendons used for glycation experiments were 0'0I--o'04mm 2 (35 days old) and 0·12--o·65mm 2 (180 days old).
Preparation of advanced glycation end products Albumin-derived AGEs were prepared by incubation of bovine serum albumin (BSA, Sigma, St Louis, MO, USA) in PBS at a concentration of 0·1 g/mL with 1·0 M glucose-6-phosphate (G-6-P, Boehringer, Mannheim, Germany) at 37°C. L-arginine was either glycated with 0·1 M or 1·0 M G-6-P. Rat tail tendons were incubated with 0·1 M G-6-P in suspensions containing approximately 20 mg rat tail tendon dry weight per 5 mL buffer. All glycation reactions were conducted under sterile conditions in buffers containing 0·1 % sodium azide, 100 mg/L penicillin, 100 U /L streptomycin. Inhibition studies were performed by adding aminoguanidinebicarbonate, arginine-lysine as acetate salt, Larginine-HCl (Sigma) or ibuprofen (Dolorgiet, St Augustin, Germany) to the incubation solutions. Inhibitor concentration was 50 mM in experiments on BSA glycation and 50 mM or 10mM in experiments with rat tail tendons. Solubilization of aminoguanidine and of ibuprofen was achieved by ultrasonic treatment and incubation at 37"C.
Quantitation of early and late glycation products Determination of non-enzymatic glycation was carried out by several methods: early glycation products were quantitated by affinity chromatography!' using m-amino-phenylboronic acid agarose gel for high capacity fractionation of Ann cu« Biochem 1996: 33 glycoproteins (carrier 6% beaded agarose, Sigma, 4 mL gel). BSA samples were dialysed against pH 8·5 wash buffer (0·2mol/L ammonium acetate, 50 rnmol/L magnesium chloride, 3 mmol/L sodium azide) to remove glucose, and diluted aliquots were passed over the phenylboronic acid column at room temperature. The bound (glycated) BSA was eluted from the column with sorbitol (0,2 mol/L, 50 mmol/L disodium EDTA, 100 mmol/L TRIS, pH 8·5). Elution was monitored at 280 nm. Non-glycated native BSA was used as a control. To determine early glycation products in rat tail tendons, the latter were cut into small pieces, extensively washed to remove G-6-P and inhibitors, lyophilized, suspended in 1mL PBS at a concentration of 4mg/mL and reduced by adding 1mg NaBH 4 , 12 containing 18·5 Mbq NaB[3H]H 4 (NEN-DuPont, Bad Homburg, Germany). After incubation for 1h at 23°C, the reaction was stopped by adjusting the pH to 4·0 with acetic acid. The specimens were exhaustively dialysed against several changes of 0·05 M acetic acid, freeze-dried, suspended in PBS and digested with type VII collagenase of bacterial origin (Sigma) for 16h at 37"C at a 1:100 weight ratio. After centrifugation at 12000 x g for 5 min, the collagen content of the clear supernatants was determined via the chloramine T assay described by Stegemann et al. 13 Efficiency of enzyme digestion was at least 98%. As an indication of the degree of early glycation product formation, the amount of sorbitol-elutable radioactivity bound to a boronic acid column was taken. Fructosamine was used as an alternative method to measure protein glycosylation, using the Roche fructosamine kit (Hoffmann-La Roche, Vienna, Austria).
For measurement of fluorophores which reflect the presence of AGEs, dialysed BSA solutions or supernatants from collagenasedigests of rat tail tendon pools were diluted with PBS, transferred to quartz cuvettes and fluorescence determined using 370 nm and 440 nm as excitation and emission wavelengths respectively on a Shimadzu spectrofluorophotometer RF 551. For rat tail tendons the fluorescence intensity was expressed in relation to the collagen content of the supernatant, i.e. fluorescence intensity per gram or milligram collagen.
[Fluorescence intensity is given in arbitrary relative fluorescence units (RFU); e.g., a solution having a fluorescence intensity of 100 at 440 nm emission wavelength has 100 RFU.]
Tensile tests and thermal contraction experiments A tensile testing device was used 14 consisting of the following main components; a spindle driven by a gear box motor, a load cell with a maximum load of 20 N and a resolution of 10mN, a potentiometer, the specimen clamps to which abrasive paper (400 grit) was glued, and a bath containing PBS. The temperature of the bath was controlled by a microprocessor-based thermostat (programmer/controller PS-962, Rikadenki). For tensile tests the temperature was kept constant at 2SOC. The reference length, i.e. the maximum length of a specimen at zero load, was 10mm. Using rat tail tendons of uniform diameter we performed uniaxial straincontrolled tensile tests at a deformation rate of I % per min. Strain values were calculated as deformation divided by original length (lOmm), i.e. as relative deformation. Load-deformation curves were continuously recorded and converted into stress-strain curves. Stress was calculated as load per gram collagen per unit length of a specimen. Young's modulus, which is defined as the tangent to the stress-strain curve, was obtained from the steepness of the linear portion of the stress-strain relationship.
Thermal isometric contraction experiments were conducted at temperatures increasing progressively from room temperature to 80 aC at a constant rate of 1aC/min. The isometric tension or contraction force developed upon heating in the tissue when mechanically restrained at its linear dimensions was recorded 15 and expressed in millivolt. This tension is the consequence of hydrothermal shrinkage, a well known characteristic of collagen fibres. Preliminary assays were performed to demonstrate the reproducibility of the isometric tension determination under varying rates of temperature increase in the saline bath. The conditions described above were chosen as the most reproducible and convenient.
STATISTICAL ANALYSIS
The unpaired Student's t-test was used for comparison between two groups. Differences were considered significant if P<O·OS.
RESULTS
As an example for soluble proteins, BSA was glycated and the formation of early glycation products as well as of AGEs was monitored in the presence or absence of inhibitors. Early glycation product formation as measured by boronic acid affinity chromatography progressed with time and was complete after nine days (Table I) , while fructosamine-saturation (Table 2 ) was obtained after 2 weeks (22'3mol fructosamine/mol BSA). At a concentration of 50 mM, neither inhibitor showed a strong inhibition of the formation of these products. The generation of fluorophores which reflects the formation of AGEs increased with incubation time reaching a plateau of 50 000 RFU after 35 days. The reaction was strongly retarded by 50 mM aminoguanidine and 50 mM ibuprofen, while addition of arginine engendered an accelerated formation rate of fluorescent products (Table 3 ). This finding may be explained by the fact that dibasic amino acids as opposed to aminoguanidine are easily fructosylated in the absence of a protein, a maximal content of fructosamine groups per mol amino acid of O· 3 for arginine (0,6 for lysine) being attained after 9 days. Arginine also rapidly formed fluorescent AGEs with 1·0 M G-6-P (Table 4) , while aminoguanidine developed only weak fluorescence and ibuprofen remained non-fluorescent.
We therefore tested, whether periodic substitution of 50 mM arginine before significant AGE-formation is initiated may prove the inhibitory quality of arginine. To this end we used 180 day rat tail tendons as an insoluble glycation target and 0·1 M G-6-P as glycating agent. Under these conditions significant soluble arginine fluorescence is not seen in the supernatant before 3 days (Fig. I) . We accordingly changed the glycation medium containing arginine every third day. Figure 2 shows that periodical substitution of arginine results in a clearcut inhibition of AGE-formation while early glycation was only marginally affected (Fig. 3) . Glucose-induced changes in Young's modulus also could be completely prevented in this way (native tendons, n = 6: 660 ±93 N mmjg; glycated tendons: 870 ± 90 N mmjg; glycated without' substitution of arginine: 867 ± 85 N mmjg; FIGURE 
Influence of different inhibitors on the formation of advanced glycation end products. Rat tail tendons from 180-day-old rats were incubated with O'i M gluose-6-phosphate and 50 mM inhibitors for 24 days at
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FIGURE 3. Influence of different inhibitors on the formation ofearly glycation products on 180-day rat tail tendons (compare Fig. 2). Rat tail tendons were reduced with borohydride and the fraction binding to a boronic acid column was determined. S.Arg: periodically substituted L-arginine. (Black columns: total tendon, shaded columns: fraction remaining on column.)
tendons glycated in the presence of periodically substituted arginine: 690 ± 72 N mrn/g, this value being significantly lower than that of both other glycated samples, P<O·OI).
Using thermal contraction experiments, we found a clearcut increase of maximal contraction force in long-term glycated rat tail tendons (35-day-old rats; glycation period 37 days) as compared to native tendons (Fig. 4 , Tables 5 and 6 ). Maximum contraction both in native and in long-term glycated tendons occurred at 64·5°C. A pronounced reduction of this maximum force was observed when glycation was performed in the presence of the inhibitors aminoguanidine and arginine-lysine, whereas ibuprofen did not significantly affect this biomechanical parameter. Although 50 mM ibuprofen was effective in inhibiting AGE-formation of soluble BSA (Table 3) , its ability to inhibit AGE-formation on rat tail tendons was disappointing (Table 5 ). However, due to the reduced solubility of ibuprofen in the absence of serum albumin, only 10 mM ibuprofen solutions could be tested in this system. The contraction experiments were therefore performed for all inhibitors at 10 mM inhibitor concentration. In addition to reducing significantly the maximum contraction force, aminoguanidine shifted the position of the peak response to lower temperatures (Table 5 ). This effect was also found when testing unglycated tendons that had been incubated with different inhibitors for three weeks at 37 DC (Table 6 , Fig. 4) . The maximal contraction force of native rat tail tendons incubated without G-6-P in the presence of 10mM ibuprofen or arginine-lysine was somewhat lower than that of rat tail tendons incubated in buffer alone. Its temperaturedependence was, however, not influenced by ibuprofen and only slightly shifted to lower temperatures by arginine-lysine. In order to determine any possible solubility effects of the different inhibitors and 0·1 M G-6-P on rat tail tendon collagen, we measured the amount of collagen solubilized during 3 weeks incubation at 37 D C. Tendon collagen was significantly solubilized only by aminoguanidine (Table 6 ).
DISCUSSION
Our previous in vitro studies provided evidence that the non-enzymatic reaction of glucose with BSA or tendon collagen results in alterations of biochemical and biomechanical properties." In the present report we performed non-enzymatic glycation with the much stronger glycating agent G-6-P and compared the inhibitory activity of the classical inhibitor aminoguanidine with that of ibuprofen as well as of L-arginine and arginine-lysine, which like aminoguanidine, conAnn Clin Biochem 1996: 33 tain a guanidino group. Neither inhibitor caused a significant inhibition of early glycation product formation. However, both aminoguanidine and ibuprofen strongly inhibited AGEformation of soluble BSA. After 9 days incubation the inhibitory effect of these inhibitors was comparable (66% versus 57%). In contrast, arginine apparently showed increased AGE-formation as judged by the fluorophores on BSA. This is due to the fact that the amino acid itself is strongly fructosylated by G-6-P and rapidly forms AGE which in turn may generate AGE-adducts on the protein target molecules. As a consequence, glycation of a mixture of protein and arginine results in an accelerated AGE-formation instead of an inhibition.
We therefore altered the arginine and arginine-lysine inhibition regime in the rat tail tendon system, i.e. in a system using an insoluble protein target, by substituting the inhibitor periodically before significant AGE-formation was initiated in the amino acid as verified by monitoring the fluorescence of the supernatant. In this way we obtained a strong inhibition comparable to that of aminoguanidine. In addition, the increase in Young's modulus due to glycation could be counteracted by the modified inhibition regime. This in vitro methodology in a way anticipates repeated daily therapeutic administration of arginine as modelled by animal systems.ls-!? The rapid in vivo elimination of arginine and its -continuous substitution by fresh inhibitor avoiding the formation of inhibitor-AGEs and at the same time inhibiting AGE-formation on plasma proteins and proteins of the extracellular matrix is a strong argument for the clinical value of this inhibitor as a potential therapeutic agent. That arginine and arginine-like amino acids should be able to block AGE-formation and of AGEderived crosslinks is suggested by Lubec et al. : 17 treatment of diabetic mice with an amino acid consisting of a guanidino group on a carbon skeleton, i.e. of a structure expected to block reactive carbonyl groups, resulted in a reduction of cross-linked collagen in renal basement membrane. 'These authors, using the fructosamine test for monitoring in vivo early glycation product formation, found a reduction in this parameter in the inhibitor-treated animals, which was, however, not statistically significant. In our hands, sodium borohydride reduction also revealed no strong decrease in early glycation product formation in rat tail tendons after 24 days incubation in D·l M G-6-P in the presence of arginine, even periodically renewed, or in the presence of aminoguanidine. Another beneficial effect of L-arginine is its recently demonstrated anti atherogenic effect which appears to be due to its metabolism to nitric oxide. IS So far, it seems that increased ingestion of this amino acid reverses the changes in vascular reactivity and reduces intimal thickness in atherosclerosis and may also reduce blood pressure and the excessive proliferation of smooth muscle cells in hypertension. These complications of diabetes mellitus have been linked to the accelerated increase in tissue AGEs that accompanies this disease.
In addition to tensile tests showing that periodically substituted arginine is also able to inhibit glucose-induced biomechanical changes, we performed thermal isometric contraction experiments on rat tail tendons. This is a wellknown method for the characterization of the stability of collagen.A'? As opposed to the tensile tests on mature rat tail tendons from 18D-day-old animals, we used tendons from 35-day-old animals for the thermal contraction experiments and collagen solubilization studies, being aware that this age is characterized by less consolidated collagen cross-links that might be especially susceptible to drugs such as aminoguanidine. We observed that glycation of rat tail tendons during five weeks resulted in a significant increase of maximal contraction force. This effect was completely inhibited by 10 mM arginine-lysine (Table 5) , while ibuprofen was inefficient as inhibitor. Although this drug was found to block AGE-formation on soluble proteins, its capacity to inhibit non-enzymatic glycation of rat tail tendons was disappointingly low. This apparent discrepancy may be explained by the fact that a large part of ibuprofen is bound to BSA,2o allowing the drug to exert its AGE-inhibiting effect both in solution and directly at the surface of the protected molecule. In contrast, binding of the acidic drug to collagen fibrils in rat tail tendons could be hampered by the alkaline isoelectric point of this connective tissue molecule. The deficient AGE-inhibition of ibuprofen in this system is reflected by its negligible effect on maximal contraction force.
Addition of aminoguanidine on the other hand caused a dramatic decrease of contraction force to a level below its value in native tendons and shifted maximum tension to lower temperatures. This temperature shift may be explained by the selective removal of the reduced collagen cross-links hydroxylysinonorleucine? which is the main crosslink in freshly synthesized collagen." This cross-link was found to be more thermally labile than crosslinks characteristic of older collagen. We observed that up to 14% of the collagen in native tail tendons, probably consisting of newly deposited highly soluble collagen, was solubilized by aminoguanidine. As a consequence, the relative amount of thermolabile cross-links could be increased. These effects of aminoguanidine on native rat tail tendons may be, however, age-dependent and less dramatic in rat tail tendons of older animals. It should be kept in mind that there is a rapid decrease in collagen solubility during maturation.lv'?
Although aminoguanidine is generally welcomed as a potent drug to inhibit AGEformation'? and eventually may find widespread use in patients with diabetes, its potential adverse side effects and toxicity cannot be overlooked. Thus, in a study on the effects of aminoguanidine on glucose toxicity in bovine retinal capillary pericytes, Chibber et al. 23 found that the drug was only slightly toxic to the pericytes but induced morphological changes with the loss of cellular processes and decreased cell spreading. This may suggest some action of aminoguanidine on the pericyte skeleton. In a diabetic mouse model/" aminoguanidine failed to protect against insulitis and hyperglycaemia induced by multiple low dose streptozotocin injections and, in addition, the mice treated with aminoguanidine showed an increased mortality. Ou et al. 25 report that aminoguanidine produces hydrogen peroxide and inhibits catalase. Our present results show that structural alterations of collagenous tissues are caused by this drug. Taken together, these observations may be of importance in proposals for the long-term administration of aminoguanidine in diabetes.
